Malaria leads to over 1 million deaths every year, 90% of which are preventable. Drug resistance is now one of the most important obstacles to effective treatment. The most economical and most widely-used drugs are not effective in most states. Medicines for Malaria Venture (MMV) was founded in 1999 with the goal of developing new artemisinin combination therapies (ACT) to efficiently treat the ailment.
A public-private-partnership, its mission is really to find, develop and deliver new treatment. With three new commodities in the conclusive stages of development and a further 30 in the pipeline, MMV faces challenges with the supply of medicines whose development is not impossible.
PUBLICATION DATE: January 31, 2009 PRODUCT #: INS059-PDF-ENG
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
KayTek: Manufacturing Housing and Livelihoods in Haiti
When There Is No Will, Is There a Way?
Infibeam Internet Retailing
Han Solar and the Green Supply Chain
Peter Schultz at the Scripps Research Institute
The Flaxil Label (C): Debrief and Endnotes
Unilever and Oxfam: Understanding the Impacts of Business on Poverty (A)
The Global Oil Industry and Latin America
Louis Robert (B): The Deal Award winner Prize Winner
Private Equity in Frontier Markets: Creating a Fund in Georgia
